食管癌的化学免疫疗法：通向更好治疗结果之路的下一步。 - Suppr | 超能文献

Chemoimmunotherapy for oesophageal cancer: the next step on the path towards better outcomes.

作者信息

Hagen Jeffrey A

机构信息

Thoracic Surgery, Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC, USA.

出版信息

Eur J Cardiothorac Surg. 2022 Aug 3;62(1). doi: 10.1093/ejcts/ezac395.

DOI:10.1093/ejcts/ezac395

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Chemoimmunotherapy for oesophageal cancer: the next step on the path towards better outcomes.食管癌的化学免疫疗法：通向更好治疗结果之路的下一步。

Eur J Cardiothorac Surg. 2022 Aug 3;62(1). doi: 10.1093/ejcts/ezac395.

2

The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer.新辅助化疗免疫治疗与放化疗治疗食管鳞癌的比较。

Eur J Cardiothorac Surg. 2022 Jun 15;62(1). doi: 10.1093/ejcts/ezac341.

3

Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?鳞状细胞食管癌的根治性或新辅助放化疗？

Lancet Oncol. 2018 Oct;19(10):1285-1286. doi: 10.1016/S1470-2045(18)30662-4. Epub 2018 Oct 1.

4

ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.ASO作者反思：局部晚期食管癌新辅助放化疗后食管切除术的时机

Ann Surg Oncol. 2023 Feb;30(2):897-898. doi: 10.1245/s10434-022-12774-9. Epub 2022 Nov 2.

5

Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.新辅助放化疗后达到临床完全缓解的食管鳞癌患者的残留癌解剖分布。

Eur J Cardiothorac Surg. 2018 Jan 1;53(1):201-208. doi: 10.1093/ejcts/ezx261.

6

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.食管鳞癌患者新辅助同步放化疗后程序性死亡配体1的肿瘤表达变化

Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.

7

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).新辅助化疗与新辅助放化疗治疗局部晚期食管鳞癌：一项单中心、开放标签、随机、对照、临床研究（HCHTOG1903）。

BMC Cancer. 2020 Apr 15;20(1):303. doi: 10.1186/s12885-020-06824-2.

8

Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010.新辅助放化疗联合手术与单纯手术治疗食管鳞癌的复发模式比较：多中心 III 期 NEOCRTEC5010 试验结果。

Eur J Cancer. 2020 Oct;138:113-121. doi: 10.1016/j.ejca.2020.08.002. Epub 2020 Aug 30.

9

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.化疗与拓益序贯给药可能影响局部晚期食管鳞癌新辅助化疗免疫疗效：一项 II 期研究。

Front Immunol. 2021 Dec 6;12:772450. doi: 10.3389/fimmu.2021.772450. eCollection 2021.

10

Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.新辅助放化疗后食管鳞癌的残余肿瘤特征。

J Thorac Cardiovasc Surg. 2021 Dec;162(6):1632-1641. doi: 10.1016/j.jtcvs.2020.09.042. Epub 2020 Sep 17.

引用本文的文献

1

Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.新辅助化疗免疫治疗与新辅助放化疗相比，可改善局部晚期食管鳞癌患者的短期生存。

Cancer Med. 2024 Aug;13(15):e70113. doi: 10.1002/cam4.70113.